Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Inventory (2024 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Inventory for 2 consecutive years, with $8.4 million as the latest value for Q4 2025.

  • Quarterly Inventory rose 60.57% to $8.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.4 million through Dec 2025, up 60.57% year-over-year, with the annual reading at $8.4 million for FY2025, 60.57% up from the prior year.
  • Inventory hit $8.4 million in Q4 2025 for ARS Pharmaceuticals, up from $7.8 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $8.7 million in Q2 2025 to a low of $715000.0 in Q3 2024.